Nanovibronix (NASDAQ:FEED – Get Free Report) is one of 29 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its rivals? We will compare Nanovibronix to similar companies based on the strength of its earnings, institutional ownership, risk, dividends, profitability, analyst recommendations and valuation.
Insider & Institutional Ownership
16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 1.4% of Nanovibronix shares are owned by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Nanovibronix and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Nanovibronix | $2.56 million | -$3.70 million | -0.06 |
| Nanovibronix Competitors | $59.54 million | -$32.15 million | 4.35 |
Profitability
This table compares Nanovibronix and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| Nanovibronix Competitors | -672.41% | -133.75% | -59.01% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Nanovibronix and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Nanovibronix Competitors | 77 | 77 | 157 | 6 | 2.29 |
As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 41.87%. Given Nanovibronix’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Nanovibronix has less favorable growth aspects than its rivals.
Volatility and Risk
Nanovibronix has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s rivals have a beta of 1.76, suggesting that their average stock price is 76% more volatile than the S&P 500.
Summary
Nanovibronix rivals beat Nanovibronix on 8 of the 13 factors compared.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
